Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

About this update from Mauna Kea Technologies Sa Class O

Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing with an existing shareholder intended to secure the Company's path to cash flow break-even Maximum dilution of approximately 11% in case of repayment in shares PARIS & BOSTON, July 15, 2026 --( BUSINESS WIRE )--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (the "Company"), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash or in new shares. This optional financing gives the Company additional resources to support its commercial growth and to seize new development opportunities. These resources would strengthen the Company's momentum, both in the United States — in the pancreatic-cyst indication and for the deployment of CellTolerance® — and internationally for these same applications. This arrangement also aims to support the continued geographic expansion of Mauna Kea Technologies into new strategic territories, following the Company's entry into Switzerland, the United Kingdom, the United Arab Emirates and Turkey during the first half of 2026. As of the date of this press release, no advance has been drawn under this arrangement. The Company may mobilize this liquidity line at its sole discretion and according to its needs, with no contractual obligation to draw. As a reminder, the Company's current financial visibility provides a cash horizon into the second quarter of 2027 without taking this advance into account or the exercise of the warrants issued as part of the November 2025 capital increase. Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, commented: "Concluded with our long-standing shareholder and partner Vester Finance, this optional arrangement, which we can mobilize at our sole initiative, provides valuable financial flexibility. As we have been experiencing favorable commercial momentum for several quarters now, it gives us the ideal room to maneuver to accelerate the commercial adoption of Cellvizio®, at the very moment when we plan to selectively strengthen our U.S. commercial force and expand the international presence of CellTolerance®." Principal terms of the shareholder loan Under the agreements entered into on July 15, 2026, Vester Finance, in its capacity as a shareholder of the Company1, has undertaken to grant the Company shareholder loan up to a maximum amount of €4.0 million, available over a period of 24 months and subject to customary contractual conditions. The Company may, at its sole discretion, request advances of up to €0.5 million each; it is under no obligation to use this arrangement. The advances are repayable either in new shares or in cash, in which case the advances bear interest at a rate of 7.0% per year from the date of payment and will mature on January 15, 2029.

View stock analysis, news, and events for Mauna Kea Technologies Sa Class O